Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals
Although HAART has resulted in improved health outcomes for most HIV-infected individuals, liver failure has emerged as a major cause of morbidity and mortality in people co-infected with hepatitis B virus (HBV). In HBV mono-infected individuals, core deletion mutants are associated with more aggres...
Gespeichert in:
Veröffentlicht in: | AIDS (London) 2007-08, Vol.21 (13), p.1701-1710 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1710 |
---|---|
container_issue | 13 |
container_start_page | 1701 |
container_title | AIDS (London) |
container_volume | 21 |
creator | REVILL, Peter A LITTLEJOHN, Margaret THIO, Chloe L LOCARNINI, Stephen A AYRES, Anna YUEN, Lilly COLLEDGE, Danni BARTHOLOMEUSZ, Angeline SASADUESZ, Joe LEWIN, Sharon R DORE, Gregory J MATTHEWS, Gail V |
description | Although HAART has resulted in improved health outcomes for most HIV-infected individuals, liver failure has emerged as a major cause of morbidity and mortality in people co-infected with hepatitis B virus (HBV). In HBV mono-infected individuals, core deletion mutants are associated with more aggressive liver disease. As HIV accelerates HBV liver disease progression, we hypothesized that HIV-HBV co-infected individuals have increased frequency of core mutations including deletions. To test this hypothesis, we have analysed genome-length sequences of HBV DNA from patients both prior to and during antiviral therapy.
Prospective HIV/HBV co-infected cohort study.
Genomic length HBV DNA was amplified by PCR from the serum samples of ten HIV/HBV co-infected individuals and five HBV mono-infected individuals prior to the commencement of lamivudine therapy and again after nine to 74 months of treatment. The complete genomes were sequenced and in order to further analyse some mutations, their frequency was determined in additional HIV/HBV co-infected and HBV mono-infected individuals.
A novel -1G mutation was identified in the HBV precore and overlapping core genes that truncated the deduced precore/core proteins. The mutant genome was the dominant species in some HIV/HBV co-infected individuals and was more prevalent in HIV/HBV co-infected individuals than HBV mono-infected individuals. The mutation was also associated with high HBV DNA concentrations in HIV/HBV co-infected individuals. Additional mutations were identified in the core/precore and polymerase genes and regulatory regions.
Mutations in the HBV core and precore genes may be contributing to disease pathogenesis in HIV/HBV co-infected individuals. |
doi_str_mv | 10.1097/QAD.0b013e32826fb305 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68147910</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68147910</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-bbd0fe5bc6b5481d4c77f5a1c8362cbe237d75e3e2832d44c1baa9026cf9a05a3</originalsourceid><addsrcrecordid>eNqFkc1LHEEQxRtJ0I3xPxDpS3Ibt_p75mg0iQtCCCReh_6oxpbZmU33zIL_fdq4ICSHXOpB8XsPqh4h5wwuGXRm_f3q5hIcMIGCt1xHJ0AdkRWTRjRKGfaGrIDrrumEgRPyrpRHAFDQtsfkhBndgdJmRZ42Acc5xeTtnKaRTpFaOk57HOgD7upuToV-ovuUl0J3Gf2Ucf08aMAB_1i2y2zHmaaR3m7u1_-6_NSkMaKfMVQopH0Kix3Ke_I2VsGzg56Sn18-_7i-be6-fd1cX901XjI-N84FiKic107JlgXpjYnKMt8Kzb1DLkwwCgXyVvAgpWfO2q5e7mNnQVlxSj6-5O7y9GvBMvfbVDwOgx1xWkqv2_qyjsF_Qc5AcS1ZBeUL6PNUSsbY73La2vzUM-ifu-lrN_3f3VTbxSF_cVsMr6ZDGRX4cABs8XaI2Y4-lVeuAym0VuI3qbWaEw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21052641</pqid></control><display><type>article</type><title>Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>REVILL, Peter A ; LITTLEJOHN, Margaret ; THIO, Chloe L ; LOCARNINI, Stephen A ; AYRES, Anna ; YUEN, Lilly ; COLLEDGE, Danni ; BARTHOLOMEUSZ, Angeline ; SASADUESZ, Joe ; LEWIN, Sharon R ; DORE, Gregory J ; MATTHEWS, Gail V</creator><creatorcontrib>REVILL, Peter A ; LITTLEJOHN, Margaret ; THIO, Chloe L ; LOCARNINI, Stephen A ; AYRES, Anna ; YUEN, Lilly ; COLLEDGE, Danni ; BARTHOLOMEUSZ, Angeline ; SASADUESZ, Joe ; LEWIN, Sharon R ; DORE, Gregory J ; MATTHEWS, Gail V</creatorcontrib><description>Although HAART has resulted in improved health outcomes for most HIV-infected individuals, liver failure has emerged as a major cause of morbidity and mortality in people co-infected with hepatitis B virus (HBV). In HBV mono-infected individuals, core deletion mutants are associated with more aggressive liver disease. As HIV accelerates HBV liver disease progression, we hypothesized that HIV-HBV co-infected individuals have increased frequency of core mutations including deletions. To test this hypothesis, we have analysed genome-length sequences of HBV DNA from patients both prior to and during antiviral therapy.
Prospective HIV/HBV co-infected cohort study.
Genomic length HBV DNA was amplified by PCR from the serum samples of ten HIV/HBV co-infected individuals and five HBV mono-infected individuals prior to the commencement of lamivudine therapy and again after nine to 74 months of treatment. The complete genomes were sequenced and in order to further analyse some mutations, their frequency was determined in additional HIV/HBV co-infected and HBV mono-infected individuals.
A novel -1G mutation was identified in the HBV precore and overlapping core genes that truncated the deduced precore/core proteins. The mutant genome was the dominant species in some HIV/HBV co-infected individuals and was more prevalent in HIV/HBV co-infected individuals than HBV mono-infected individuals. The mutation was also associated with high HBV DNA concentrations in HIV/HBV co-infected individuals. Additional mutations were identified in the core/precore and polymerase genes and regulatory regions.
Mutations in the HBV core and precore genes may be contributing to disease pathogenesis in HIV/HBV co-infected individuals.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/QAD.0b013e32826fb305</identifier><identifier>PMID: 17690567</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>AIDS/HIV ; Antiretroviral Therapy, Highly Active ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; DNA, Viral - blood ; DNA, Viral - genetics ; Gene Deletion ; Genome, Viral ; Hepatitis B virus ; Hepatitis B virus - genetics ; Hepatitis B virus - isolation & purification ; Hepatitis B, Chronic - complications ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - virology ; HIV Infections - complications ; HIV Infections - drug therapy ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Lamivudine - therapeutic use ; Medical sciences ; Polymerase Chain Reaction - methods ; Prospective Studies ; Sequence Analysis, DNA - methods ; Viral Core Proteins - genetics ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral hepatitis</subject><ispartof>AIDS (London), 2007-08, Vol.21 (13), p.1701-1710</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-bbd0fe5bc6b5481d4c77f5a1c8362cbe237d75e3e2832d44c1baa9026cf9a05a3</citedby><cites>FETCH-LOGICAL-c412t-bbd0fe5bc6b5481d4c77f5a1c8362cbe237d75e3e2832d44c1baa9026cf9a05a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19043665$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17690567$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>REVILL, Peter A</creatorcontrib><creatorcontrib>LITTLEJOHN, Margaret</creatorcontrib><creatorcontrib>THIO, Chloe L</creatorcontrib><creatorcontrib>LOCARNINI, Stephen A</creatorcontrib><creatorcontrib>AYRES, Anna</creatorcontrib><creatorcontrib>YUEN, Lilly</creatorcontrib><creatorcontrib>COLLEDGE, Danni</creatorcontrib><creatorcontrib>BARTHOLOMEUSZ, Angeline</creatorcontrib><creatorcontrib>SASADUESZ, Joe</creatorcontrib><creatorcontrib>LEWIN, Sharon R</creatorcontrib><creatorcontrib>DORE, Gregory J</creatorcontrib><creatorcontrib>MATTHEWS, Gail V</creatorcontrib><title>Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>Although HAART has resulted in improved health outcomes for most HIV-infected individuals, liver failure has emerged as a major cause of morbidity and mortality in people co-infected with hepatitis B virus (HBV). In HBV mono-infected individuals, core deletion mutants are associated with more aggressive liver disease. As HIV accelerates HBV liver disease progression, we hypothesized that HIV-HBV co-infected individuals have increased frequency of core mutations including deletions. To test this hypothesis, we have analysed genome-length sequences of HBV DNA from patients both prior to and during antiviral therapy.
Prospective HIV/HBV co-infected cohort study.
Genomic length HBV DNA was amplified by PCR from the serum samples of ten HIV/HBV co-infected individuals and five HBV mono-infected individuals prior to the commencement of lamivudine therapy and again after nine to 74 months of treatment. The complete genomes were sequenced and in order to further analyse some mutations, their frequency was determined in additional HIV/HBV co-infected and HBV mono-infected individuals.
A novel -1G mutation was identified in the HBV precore and overlapping core genes that truncated the deduced precore/core proteins. The mutant genome was the dominant species in some HIV/HBV co-infected individuals and was more prevalent in HIV/HBV co-infected individuals than HBV mono-infected individuals. The mutation was also associated with high HBV DNA concentrations in HIV/HBV co-infected individuals. Additional mutations were identified in the core/precore and polymerase genes and regulatory regions.
Mutations in the HBV core and precore genes may be contributing to disease pathogenesis in HIV/HBV co-infected individuals.</description><subject>AIDS/HIV</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>DNA, Viral - blood</subject><subject>DNA, Viral - genetics</subject><subject>Gene Deletion</subject><subject>Genome, Viral</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis B virus - isolation & purification</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - virology</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Lamivudine - therapeutic use</subject><subject>Medical sciences</subject><subject>Polymerase Chain Reaction - methods</subject><subject>Prospective Studies</subject><subject>Sequence Analysis, DNA - methods</subject><subject>Viral Core Proteins - genetics</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral hepatitis</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1LHEEQxRtJ0I3xPxDpS3Ibt_p75mg0iQtCCCReh_6oxpbZmU33zIL_fdq4ICSHXOpB8XsPqh4h5wwuGXRm_f3q5hIcMIGCt1xHJ0AdkRWTRjRKGfaGrIDrrumEgRPyrpRHAFDQtsfkhBndgdJmRZ42Acc5xeTtnKaRTpFaOk57HOgD7upuToV-ovuUl0J3Gf2Ucf08aMAB_1i2y2zHmaaR3m7u1_-6_NSkMaKfMVQopH0Kix3Ke_I2VsGzg56Sn18-_7i-be6-fd1cX901XjI-N84FiKic107JlgXpjYnKMt8Kzb1DLkwwCgXyVvAgpWfO2q5e7mNnQVlxSj6-5O7y9GvBMvfbVDwOgx1xWkqv2_qyjsF_Qc5AcS1ZBeUL6PNUSsbY73La2vzUM-ifu-lrN_3f3VTbxSF_cVsMr6ZDGRX4cABs8XaI2Y4-lVeuAym0VuI3qbWaEw</recordid><startdate>20070820</startdate><enddate>20070820</enddate><creator>REVILL, Peter A</creator><creator>LITTLEJOHN, Margaret</creator><creator>THIO, Chloe L</creator><creator>LOCARNINI, Stephen A</creator><creator>AYRES, Anna</creator><creator>YUEN, Lilly</creator><creator>COLLEDGE, Danni</creator><creator>BARTHOLOMEUSZ, Angeline</creator><creator>SASADUESZ, Joe</creator><creator>LEWIN, Sharon R</creator><creator>DORE, Gregory J</creator><creator>MATTHEWS, Gail V</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20070820</creationdate><title>Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals</title><author>REVILL, Peter A ; LITTLEJOHN, Margaret ; THIO, Chloe L ; LOCARNINI, Stephen A ; AYRES, Anna ; YUEN, Lilly ; COLLEDGE, Danni ; BARTHOLOMEUSZ, Angeline ; SASADUESZ, Joe ; LEWIN, Sharon R ; DORE, Gregory J ; MATTHEWS, Gail V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-bbd0fe5bc6b5481d4c77f5a1c8362cbe237d75e3e2832d44c1baa9026cf9a05a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>AIDS/HIV</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>DNA, Viral - blood</topic><topic>DNA, Viral - genetics</topic><topic>Gene Deletion</topic><topic>Genome, Viral</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis B virus - isolation & purification</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - virology</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Lamivudine - therapeutic use</topic><topic>Medical sciences</topic><topic>Polymerase Chain Reaction - methods</topic><topic>Prospective Studies</topic><topic>Sequence Analysis, DNA - methods</topic><topic>Viral Core Proteins - genetics</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>REVILL, Peter A</creatorcontrib><creatorcontrib>LITTLEJOHN, Margaret</creatorcontrib><creatorcontrib>THIO, Chloe L</creatorcontrib><creatorcontrib>LOCARNINI, Stephen A</creatorcontrib><creatorcontrib>AYRES, Anna</creatorcontrib><creatorcontrib>YUEN, Lilly</creatorcontrib><creatorcontrib>COLLEDGE, Danni</creatorcontrib><creatorcontrib>BARTHOLOMEUSZ, Angeline</creatorcontrib><creatorcontrib>SASADUESZ, Joe</creatorcontrib><creatorcontrib>LEWIN, Sharon R</creatorcontrib><creatorcontrib>DORE, Gregory J</creatorcontrib><creatorcontrib>MATTHEWS, Gail V</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>REVILL, Peter A</au><au>LITTLEJOHN, Margaret</au><au>THIO, Chloe L</au><au>LOCARNINI, Stephen A</au><au>AYRES, Anna</au><au>YUEN, Lilly</au><au>COLLEDGE, Danni</au><au>BARTHOLOMEUSZ, Angeline</au><au>SASADUESZ, Joe</au><au>LEWIN, Sharon R</au><au>DORE, Gregory J</au><au>MATTHEWS, Gail V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2007-08-20</date><risdate>2007</risdate><volume>21</volume><issue>13</issue><spage>1701</spage><epage>1710</epage><pages>1701-1710</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>Although HAART has resulted in improved health outcomes for most HIV-infected individuals, liver failure has emerged as a major cause of morbidity and mortality in people co-infected with hepatitis B virus (HBV). In HBV mono-infected individuals, core deletion mutants are associated with more aggressive liver disease. As HIV accelerates HBV liver disease progression, we hypothesized that HIV-HBV co-infected individuals have increased frequency of core mutations including deletions. To test this hypothesis, we have analysed genome-length sequences of HBV DNA from patients both prior to and during antiviral therapy.
Prospective HIV/HBV co-infected cohort study.
Genomic length HBV DNA was amplified by PCR from the serum samples of ten HIV/HBV co-infected individuals and five HBV mono-infected individuals prior to the commencement of lamivudine therapy and again after nine to 74 months of treatment. The complete genomes were sequenced and in order to further analyse some mutations, their frequency was determined in additional HIV/HBV co-infected and HBV mono-infected individuals.
A novel -1G mutation was identified in the HBV precore and overlapping core genes that truncated the deduced precore/core proteins. The mutant genome was the dominant species in some HIV/HBV co-infected individuals and was more prevalent in HIV/HBV co-infected individuals than HBV mono-infected individuals. The mutation was also associated with high HBV DNA concentrations in HIV/HBV co-infected individuals. Additional mutations were identified in the core/precore and polymerase genes and regulatory regions.
Mutations in the HBV core and precore genes may be contributing to disease pathogenesis in HIV/HBV co-infected individuals.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>17690567</pmid><doi>10.1097/QAD.0b013e32826fb305</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-9370 |
ispartof | AIDS (London), 2007-08, Vol.21 (13), p.1701-1710 |
issn | 0269-9370 1473-5571 |
language | eng |
recordid | cdi_proquest_miscellaneous_68147910 |
source | MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
subjects | AIDS/HIV Antiretroviral Therapy, Highly Active Antiviral Agents - therapeutic use Biological and medical sciences DNA, Viral - blood DNA, Viral - genetics Gene Deletion Genome, Viral Hepatitis B virus Hepatitis B virus - genetics Hepatitis B virus - isolation & purification Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology HIV Infections - complications HIV Infections - drug therapy Human immunodeficiency virus Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Lamivudine - therapeutic use Medical sciences Polymerase Chain Reaction - methods Prospective Studies Sequence Analysis, DNA - methods Viral Core Proteins - genetics Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral hepatitis |
title | Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A12%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20a%20novel%20hepatitis%20B%20virus%20precore/core%20deletion%20mutant%20in%20HIV/hepatitis%20B%20virus%20co-infected%20individuals&rft.jtitle=AIDS%20(London)&rft.au=REVILL,%20Peter%20A&rft.date=2007-08-20&rft.volume=21&rft.issue=13&rft.spage=1701&rft.epage=1710&rft.pages=1701-1710&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/QAD.0b013e32826fb305&rft_dat=%3Cproquest_cross%3E68147910%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21052641&rft_id=info:pmid/17690567&rfr_iscdi=true |